Cancer drug dasatinib shows promise in early HIV control trial
NCT ID NCT05527418
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests whether dasatinib, a drug currently used for leukemia, can safely control HIV in people who were infected within the past 3 to 12 months and have not yet taken standard HIV medications. Participants receive either dasatinib or a placebo for 16 weeks. The goal is to see if dasatinib can lower the amount of virus in the blood and reduce the hidden viral reservoirs that make HIV hard to cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dasatinib
- What this could lead to
- If successful, dasatinib might offer a new way to control HIV early after infection, possibly reducing the need for lifelong antiretroviral therapy.
- What could go wrong
- This is a small, early-phase trial. Dasatinib is a cancer drug with known side effects, and it may not effectively control HIV or reduce viral reservoirs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECENT HIV-1 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Eva Bonfill
Barcelona, Spain